GC Cell

GC Cell Net Debt per Share

The Net Debt per Share of GC Cell (144510.KQ) as of Nov 1, 2026 is 5,296.62 KRW. In the previous year, Net Debt per Share was 5,248.82 KRW — a change of 0.91% (higher).

Net Debt per Share

5,296.62KRW

YoY

0.91%

Last updated:

Net Debt per Share of GC Cell is 2024 5,296.62 KRW. Net Debt per Share of GC Cell was 2023 5,248.82 KRW. It decreases by 0.91% higher compared to the previous year.

The GC Cell Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2017
-2,567.66 KRW
Jan 1, 2018
-1,882.44 KRW
Jan 1, 2019
-419.26 KRW
Jan 1, 2020
-332.05 KRW
Jan 1, 2021
3,318.18 KRW
Jan 1, 2022
1,841.70 KRW
Jan 1, 2023
5,248.82 KRW
Jan 1, 2024
5,296.62 KRW
The GC Cell Net Debt per Share history
YEARNet Debt per ShareYoY
5,296.62KRW+0.91%
5,248.82KRW+185.00%
1,841.70KRW-44.50%
3,318.18KRW-1,099.31%
-332.05KRW-20.80%
-419.26KRW-77.73%
-1,882.44KRW-26.69%
-2,567.66KRW-2.11%
-2,622.99KRW+920.96%
-256.91KRW-18.31%
-314.51KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GC Cell Stock analysis

What does GC Cell do? GC Cell Corp generates revenue through four business segments. The Specimen Testing Service segment offers sample testing, clinical trial support, and veterinary testing services to clients in healthcare and research sectors. The Cell Therapy segment provides cell culture solutions and technology transfer services to biotechnology firms. The Cord Blood Storage segment delivers cord blood storage services primarily to expectant parents and medical institutions. The Other Business segment handles bio-logistics services and related operations for healthcare providers. The company's revenue streams are derived from direct contracts with healthcare organizations, biotech companies, and individual clients seeking specialized testing and storage solutions. Clients include hospitals, research institutions, and private individuals requiring cord blood preservation. The firm's business model focuses on providing specialized services within the life sciences sector without relying on external partnerships or third-party platforms. GC Cell Corp's product offerings are tailored to specific industry needs, with each segment targeting distinct client groups. The Specimen Testing Service segment serves clients needing laboratory analysis, while the Cell Therapy segment supports biotech innovation through technology transfer. The Cord Blood Storage segment caters to consumer demand for personal health preservation, and the Other Business segment facilitates logistics for medical supply chains. GC Cell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Cell stock

Net Debt per Share of GC Cell is 5,296.62 KRW in 2024.

Net Debt per Share of GC Cell changed from 5,248.82 KRW to 5,296.62 KRW, representing a 0.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share GC Cell since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — GC Cell

All Key Metrics — GC Cell